Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2
Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2
Арутюнов Г.П., Тарловская Е.И., Козиолова Н.А. и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2. Терапевтический архив. 2020; 92 (9): 108–124. DOI: 10.26442/00403660.2020.09.000703
________________________________________________
Arutiunov G.P., Tarlovskaia E.I., Koziolova N.A., et al. The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2. Therapeutic Archive. 2020; 92 (9): 108–124. DOI: 10.26442/00403660.2020.09.000703
Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2
Арутюнов Г.П., Тарловская Е.И., Козиолова Н.А. и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2. Терапевтический архив. 2020; 92 (9): 108–124. DOI: 10.26442/00403660.2020.09.000703
________________________________________________
Arutiunov G.P., Tarlovskaia E.I., Koziolova N.A., et al. The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2. Therapeutic Archive. 2020; 92 (9): 108–124. DOI: 10.26442/00403660.2020.09.000703
В соглашении экспертов Евразийской ассоциации терапевтов (ЕАТ) обсуждаются вопросы патогенеза и лечения COVID-19. Представлены современные данные об особенностях поражения сердечно-сосудистой системы, почек, органов дыхания у инфицированных SARS-Cov-2. Подробно обсуждена тактика ведения пациентов, исходно имеющих сердечно-сосудистые заболевания, сахарный диабет, хроническую обструктивную болезнь легких, бронхиальную астму, хроническую болезнь почек.
В статье представлены данные о лекарственном взаимодействии препаратов.
The agreement of experts of the Eurasian Association of Therapists (EAT) discusses pathogenesis and treatment of COVID-19. Modern data on the characteristics of cardiovascular, kidney, respiratory damage in SARS-infected CoV-2 are presented. The tactics of managing patients initially having cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, bronchial asthma, chronic kidney disease are discussed in detail. The article presents data on drug interaction of drugs.
1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12. pii: S1201-9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017
2. Wang B, Li R, Hufng Y, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020 Apr 8;12. doi: 10.18632/aging.103000
3. Wei-jie Guan, Wen-hua Liang, Yi Zhao, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020. doi: 10.1183/13993003.00547-2020
4. Chow N, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020 Apr 3;69:382. doi: 10.15585/mmwr.mm6913e2
5. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. ePub: 8 April 2020. doi: 10.15585/mmwr.mm6915e3
6. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020. China CDC Weekly. 2020;2(8):10. doi: 10.46234/ccdcw2020.032
7. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) United States, February 12–March 16, 2020. CDC Morbidity and Mortality Weekly Report. 2020;69. doi: 10.15585/mmwr.mm6912e2
8. Report sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia Il presente report è basato sui dati aggiornati al 20 Marzo 2020. Istituto Superioe di Sanita, 2020. https://www.epicentro.iss.it/coronavirus/
sars-cov-2-decessi-italia
9. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. J Am Med Assoc. 2020 Mar 23. doi: 10.1001/jama.2020.4683
10. Covid-19. Situation au 15 mars 2020 à minuit. Santé publique France, 2020. 18.03.2020. https://www.caducee.net/actualite-medicale/14761/covid-19-le-point-de-situation-epidemiologique-sur-...
11. Ki M. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiol Health. 2020;42:e2020007. doi: 10.4178/epih.e2020007
12. Barns rolle i spredning av SARS-CoV-2 (Covid-19) – en hurtigoversikt. Hurtigoppsummering. Oslo: Folkehelseinstituttet, 2020. 23.03.2020. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/barns-rolle-i-spredning--av-sars-cov-...
13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease Control and prevention. J Am Med Assoc. 2020 Feb 24. doi: 10.1001/jama.2020.2648
14. Palmieri L, Andrianou X, Bella A, et al. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf
15. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 March 25. doi: 10.1001/jamacardio.2020.0950
16. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 March 27. doi: 10.1001/jamacardio.2020.1017
17. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 Mar 11. doi: 10.1007/s00392-020-01626-9.
18. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 March 27. doi: 10.1001/jamacardio.2020.1286
19. Профилактика, диагностика и лечение новой коронавирусной инфекции (2019-nCoV). Временные методические рекомендации. Минздрав России. Версия V. 08.04.2020 [Prevention, diagnosis and treatment of a new coronavirus infection (2019-nCoV). The provisional guidelines. Ministry of Health of Russia. Version V. 08.04.2020 (In Russ.)]. https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020_%D0%9C%D0%...
20. Шляхто Е.В., Конради А.О., Арутюнов Г. П и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801 [Shlyakhto EV, Konradi A O, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801 (In Russ.)]. doi: 10.15829/1560-4071-2020-3-3801
21. Massachusetts General Hospital COVID-19. Treatment Guidance Version 1.36, 4/5/2020 5:00PM. The General Hospital Corporation. All Rights Reserved. https://medach.pro/post/2322
22. The Liverpool Drug Interaction Group. https://www.covid19-druginteractions.org/
23. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136
24. Lane JCE, Weaver J, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. doi: 10.1101/2020.04.08.20054551
25. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Mar 29, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-t...
26. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. March 30 2020. doi: 10.1056/NEJMsr2005760
27. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9. doi: 10.1038 / nm1267
28. Mitchel L. Zoler Evidence Suggests Possible RAS-Blocker Benefit in Patients With COVID-19 Medscape Medical News. April 17 2020. https://www.medscape.com/viewarticle/928902?src=soc_fb_share
29. Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31(4):419-23. doi: 10.1080/08998280.2018.1499293
30. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv preprint. doi: 10.1101/2020.03.20.20039586
31. 18.03.2020 HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 – American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-...
32. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers 13 Mar 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-c...
33. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? March 11, 2020. doi: 10.1016/S2213-2600(20)30116-8
34. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99:417-35. doi: 10.1016/j.antiviral.2013.06.018
35. Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020. doi: 10.1038/s41569-020-0360-5
36. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020 Apr 2. doi: 10.1007/s11684-020-0767-8
37. Danzi G, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;ehaa254. doi: 10.1093/eurheartj/ehaa254
38. Jecko Thachil, Ning Tang, Satoshi Gando et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14810
39. Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. 25th March 2020. https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf
40. World Health Organization. Cardiovascular diseases (CVDs) Fact sheet No 317. Internet. 2015 Jan. http://www.who.int/mediacentre/factsheets/fs317/en//
41. Tancredi M, Rosengren A, Svensson AM, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373:1720-32. doi: 10.1056/NEJMoa1504347
42. Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6):623e8. doi: 10.1111/j.1464-5491.2006.01861.x
43. Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010;33(7):1491e3. doi: 10.2337/dc09-2215
44. Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: a case control study of hospitalized patients. Clin Infect Dis. 2014;59:160e5. doi: 10.1093/cid/ciu226.
45. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans. Saudi Arabia 2014. Emerg Infect Dis 2016;22:49e55. doi: 10.3201/eid2201.151340
46. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020 Mar 28. doi: 10.1007/s40618-020-01236-2
47. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 d United States, February 12 – March 28, 2020. CDC COVID-19 response team. https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
48. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497e506. doi: 10.1016/S0140-6736(20)30183-5
49. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronaviruse infected pneumonia in wuhan, China. J Am Med Assoc. 2020;323(11):1061e9. doi: 10.1001/jama.2020.1585
50. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238
51. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. 2020 March 13. doi: 10.1001/jamainternmed.2020.0994
52. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-64. doi: 10.15585/mmwr.mm6915e3
53. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. March 2020;9. doi: 10.1016/S0140-6736(20)30566-3
54. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020 Feb 24. doi: 10.1001/jama.2020.2648
55. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193e9. doi: 10.1007/s00592-009-0109-4
56. Liu W, Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. Preprint. 2020. doi: 10.26434/chemrxiv.11938173.v7
57. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020;108146. doi: 10.1016/j.diabres.2020.108146
58. Knapp S. Diabetes and infection: is there a link? – A minireview clinical section/mini-review. Gerontology. 2013;59:99-104. doi: 10.1159/000345107
59. Badawi A, Ryoo SG. Prevalence of diabetes in the 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus: a systematic review and meta-analysis. J Public Health Res. 2016;5(3):733. doi: 10.4081/jphr.2016.733
60. Ma WX, Ran XW. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(2):146-50. doi: 10.12182/20200360606
61. Yao RQ, Ren C, Wu GS, et al. Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis. Int J Biol Sci. 2020;16(9):1658-75. doi: 10.7150/ijbs.43447
62. Available from: http://www.almazovcentre.ru/?p=62944
63. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-31. doi: 10.4158/EP09102.RA
64. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9. doi: 10.1016/S0140-6736(18)32590-X
65. Hallow KM, Greasley PJ, Helmlinger G, et al. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol. 2018;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018
66. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med. 2017;376(23):2300-02. doi: 10.1056/NEJMc1701990
67. Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020;43(2):468-75. doi: 10.2337/dc19-1476
68. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105-13. doi: 10.1016/S2213-8587(17)30412-6
69. Nassif ME, Kosiborod M. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. Am J Cardiol. 2019;124(Suppl. 1):S12-S19. doi: 10.1016/j.amjcard.2019.10.025
70. Romaní-Perez M, Outeirino-Iglesias V, Moya CM, et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 2015;156(10):3559e69. doi: 10.1210/en.2014-1685
71. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827
72. Muniyappa R, Gubbi S. COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Am J Physiol Endocrinol Metab. 2020 Mar 31. doi: 10.1152/ajpendo.00124.2020
73. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162
74. Available from: https://webinar-endo.ru/archive/08042020koronavirusnaya-infekciya-covid-19-i-saharnyy-diabet-chto-iz...
75. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4
76. Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart FailureAssociation of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853-72. doi: 10.1002/ejhf.1170
77. Verma S, Goldenberg R, Bhatt D, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open. 2017;5(1):E152-E177. doi: 10.9778/cmajo.20160058
78. Iacobellis G. COVID-19 and Diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125. doi: 10.1016/
j.diabres.2020.108125
79. Gorricho J, Garjon J, Alonso A, et al. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin Pharmacol. 2017;83(9):2034e44. doi: 10.1111/bcp.13288
80. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illnessin humans. Saudi Arabia 2014. Emerg Infect Dis 2016;22:49e55. doi: 10.3201/eid2201.151340
81. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother [Internet]. 2020 Mar 25. https://academic.
oup.com/jac/advance-article/doi/10.1093/jac/dkaa114/5810487
82. Brufsky A. Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.2588
83. Jin-Jin Zhang, Xiang Dong, Yi-Yuan Cao, et al. Clinical Characteristics of 140 Patients Infected With SARS-CoV-2 in Wuhan, China. 2020 Feb 19. doi: 10.1111/all.14238
84. Guan WJ, Ni ZY, Hu Y, et al., for the China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. doi: 10.1056/NEJMoa2002032
85. Xiaochen Li, Shuyun Xu, Muqing Yu, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. Journal of Allergy and Clinical Immunology. 2020 Apr 9. doi: 10.1016/j.jaci.2020.04.006
86. Yang Jing, Ya Zheng, Xi Gou, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12. doi: 10.1016/j.ijid.2020.03.017
87. Vardava CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence Tob Induc Dis. 2020;18:20. doi: 10.18332/tid/119324
88. Global initiative for asthma (GINA) 2020. https://ginasthma.org/
gina-reports/
89. Global initiative on chronic obstructive pulmonary disease (GOLD) 2020. https://goldcopd.org/gold-covid-19-guidance/
90. Naicker S, Yang CW, Hwang SJ, et al. The Novel Coronavirus 2019 Epidemic and Kidneys. Kidney Int. 2020. doi: 10.1016/j.kint.2020.03.001
91. Pan X-W, Xu D, Zhang H, et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020. 17.04.2020. doi: 10.1007/s00134-020-06026-1
92. Yao X, Li T, He Z, et al. Histopathological study on multiple sites of puncture of the remains of 3 cases of novel coronavirus pneumonia (COVID-19). Chin J Pathol. 2020;49. doi: 10.3760/cma.j.cn112151-20200312-00193
93. Huang C, Wang Y, Li X, et al. Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
94. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;201585. doi: 10.1001/jama.2020.1585
95. Yang X, Yu Y, Xu J, et al. Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
96. Deng Y, Liu W, Liu K, et al. Clinical Characteristics of Fatal and Recovered Cases of Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Retrospective Study. Chin Med J (Engl). 2020. doi: 10.1097/CM9.0000000000000824
97. Cheng Y, Luo R, Wang K, et al. Kidney Disease Is Associated With In-Hospital Death of Patients With COVID-19. Kidney Int. 2020;S0085-2538(20):30255-6. doi: 10.1016/j.kint.2020.03.005
98. Ma Y, Diao B, Lv X, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, China. Blog – NephJC. 2020. doi: 10.1101/2020.02.24.20027201
99. Информация по коронавирусной инфекции COVID-19. Ассоциация Нефрологов. 17.04.2020 [Information on COVID-19 coronavirus infection. Association of Nephrologists. 17.04.2020 (In Russ.)]. http://www.rusnephrology.org/professional/
100. Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney Int. 2020. doi: 10.1016/j.kint.2020.03.015
101. Available from: https://www.era-edta.org/en/covid-19-newsand-information/#toggle-id-23
________________________________________________
1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12. pii: S1201-9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017
2. Wang B, Li R, Hufng Y, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020 Apr 8;12. doi: 10.18632/aging.103000
3. Wei-jie Guan, Wen-hua Liang, Yi Zhao, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020. doi: 10.1183/13993003.00547-2020
4. Chow N, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020 Apr 3;69:382. doi: 10.15585/mmwr.mm6913e2
5. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. ePub: 8 April 2020. doi: 10.15585/mmwr.mm6915e3
6. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020. China CDC Weekly. 2020;2(8):10. doi: 10.46234/ccdcw2020.032
7. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) United States, February 12–March 16, 2020. CDC Morbidity and Mortality Weekly Report. 2020;69. doi: 10.15585/mmwr.mm6912e2
8. Report sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia Il presente report è basato sui dati aggiornati al 20 Marzo 2020. Istituto Superioe di Sanita, 2020. https://www.epicentro.iss.it/coronavirus/
sars-cov-2-decessi-italia
9. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. J Am Med Assoc. 2020 Mar 23. doi: 10.1001/jama.2020.4683
10. Covid-19. Situation au 15 mars 2020 à minuit. Santé publique France, 2020. 18.03.2020. https://www.caducee.net/actualite-medicale/14761/covid-19-le-point-de-situation-epidemiologique-sur-...
11. Ki M. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiol Health. 2020;42:e2020007. doi: 10.4178/epih.e2020007
12. Barns rolle i spredning av SARS-CoV-2 (Covid-19) – en hurtigoversikt. Hurtigoppsummering. Oslo: Folkehelseinstituttet, 2020. 23.03.2020. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/barns-rolle-i-spredning--av-sars-cov-...
13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease Control and prevention. J Am Med Assoc. 2020 Feb 24. doi: 10.1001/jama.2020.2648
14. Palmieri L, Andrianou X, Bella A, et al. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf
15. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 March 25. doi: 10.1001/jamacardio.2020.0950
16. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 March 27. doi: 10.1001/jamacardio.2020.1017
17. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 Mar 11. doi: 10.1007/s00392-020-01626-9.
18. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 March 27. doi: 10.1001/jamacardio.2020.1286
19. Prevention, diagnosis and treatment of a new coronavirus infection (2019-nCoV). The provisional guidelines. Ministry of Health of Russia. Version V. 08.04.2020 (In Russ.) https://static1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020_%D0%9C%D0%...
20. Shlyakhto EV, Konradi A O, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801 (In Russ.) doi: 10.15829/1560-4071-2020-3-3801
21. Massachusetts General Hospital COVID-19. Treatment Guidance Version 1.36, 4/5/2020 5:00PM. The General Hospital Corporation. All Rights Reserved. https://medach.pro/post/2322
22. The Liverpool Drug Interaction Group. https://www.covid19-druginteractions.org/
23. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136
24. Lane JCE, Weaver J, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. doi: 10.1101/2020.04.08.20054551
25. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Mar 29, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-t...
26. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. March 30 2020. doi: 10.1056/NEJMsr2005760
27. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9. doi: 10.1038 / nm1267
28. Mitchel L. Zoler Evidence Suggests Possible RAS-Blocker Benefit in Patients With COVID-19 Medscape Medical News. April 17 2020. https://www.medscape.com/viewarticle/928902?src=soc_fb_share
29. Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31(4):419-23. doi: 10.1080/08998280.2018.1499293
30. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv preprint. doi: 10.1101/2020.03.20.20039586
31. 18.03.2020 HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 – American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-...
32. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers 13 Mar 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-c...
33. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? March 11, 2020. doi: 10.1016/S2213-2600(20)30116-8
34. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99:417-35. doi: 10.1016/j.antiviral.2013.06.018
35. Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020. doi: 10.1038/s41569-020-0360-5
36. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020 Apr 2. doi: 10.1007/s11684-020-0767-8
37. Danzi G, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;ehaa254. doi: 10.1093/eurheartj/ehaa254
38. Jecko Thachil, Ning Tang, Satoshi Gando et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14810
39. Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. 25th March 2020. https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf
40. World Health Organization. Cardiovascular diseases (CVDs) Fact sheet No 317. Internet. 2015 Jan. http://www.who.int/mediacentre/factsheets/fs317/en//
41. Tancredi M, Rosengren A, Svensson AM, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373:1720-32. doi: 10.1056/NEJMoa1504347
42. Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6):623e8. doi: 10.1111/j.1464-5491.2006.01861.x
43. Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010;33(7):1491e3. doi: 10.2337/dc09-2215
44. Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: a case control study of hospitalized patients. Clin Infect Dis. 2014;59:160e5. doi: 10.1093/cid/ciu226.
45. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans. Saudi Arabia 2014. Emerg Infect Dis 2016;22:49e55. doi: 10.3201/eid2201.151340
46. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020 Mar 28. doi: 10.1007/s40618-020-01236-2
47. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 d United States, February 12 – March 28, 2020. CDC COVID-19 response team. https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm
48. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497e506. doi: 10.1016/S0140-6736(20)30183-5
49. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronaviruse infected pneumonia in wuhan, China. J Am Med Assoc. 2020;323(11):1061e9. doi: 10.1001/jama.2020.1585
50. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238
51. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. 2020 March 13. doi: 10.1001/jamainternmed.2020.0994
52. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-64. doi: 10.15585/mmwr.mm6915e3
53. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. March 2020;9. doi: 10.1016/S0140-6736(20)30566-3
54. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020 Feb 24. doi: 10.1001/jama.2020.2648
55. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193e9. doi: 10.1007/s00592-009-0109-4
56. Liu W, Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. Preprint. 2020. doi: 10.26434/chemrxiv.11938173.v7
57. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020;108146. doi: 10.1016/j.diabres.2020.108146
58. Knapp S. Diabetes and infection: is there a link? – A minireview clinical section/mini-review. Gerontology. 2013;59:99-104. doi: 10.1159/000345107
59. Badawi A, Ryoo SG. Prevalence of diabetes in the 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus: a systematic review and meta-analysis. J Public Health Res. 2016;5(3):733. doi: 10.4081/jphr.2016.733
60. Ma WX, Ran XW. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(2):146-50. doi: 10.12182/20200360606
61. Yao RQ, Ren C, Wu GS, et al. Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis. Int J Biol Sci. 2020;16(9):1658-75. doi: 10.7150/ijbs.43447
62. Available from: http://www.almazovcentre.ru/?p=62944
63. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-31. doi: 10.4158/EP09102.RA
64. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9. doi: 10.1016/S0140-6736(18)32590-X
65. Hallow KM, Greasley PJ, Helmlinger G, et al. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol. 2018;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018
66. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med. 2017;376(23):2300-02. doi: 10.1056/NEJMc1701990
67. Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020;43(2):468-75. doi: 10.2337/dc19-1476
68. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105-13. doi: 10.1016/S2213-8587(17)30412-6
69. Nassif ME, Kosiborod M. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. Am J Cardiol. 2019;124(Suppl. 1):S12-S19. doi: 10.1016/j.amjcard.2019.10.025
70. Romaní-Perez M, Outeirino-Iglesias V, Moya CM, et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 2015;156(10):3559e69. doi: 10.1210/en.2014-1685
71. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827
72. Muniyappa R, Gubbi S. COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Am J Physiol Endocrinol Metab. 2020 Mar 31. doi: 10.1152/ajpendo.00124.2020
73. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162
74. Available from: https://webinar-endo.ru/archive/08042020koronavirusnaya-infekciya-covid-19-i-saharnyy-diabet-chto-iz...
75. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4
76. Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart FailureAssociation of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853-72. doi: 10.1002/ejhf.1170
77. Verma S, Goldenberg R, Bhatt D, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open. 2017;5(1):E152-E177. doi: 10.9778/cmajo.20160058
78. Iacobellis G. COVID-19 and Diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125. doi: 10.1016/j.diabres.2020.108125
79. Gorricho J, Garjon J, Alonso A, et al. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin Pharmacol. 2017;83(9):2034e44. doi: 10.1111/bcp.13288
80. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illnessin humans. Saudi Arabia 2014. Emerg Infect Dis 2016;22:49e55. doi: 10.3201/eid2201.151340
81. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother [Internet]. 2020 Mar 25. https://academic.
oup.com/jac/advance-article/doi/10.1093/jac/dkaa114/5810487
82. Brufsky A. Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.2588
83. Jin-Jin Zhang, Xiang Dong, Yi-Yuan Cao, et al. Clinical Characteristics of 140 Patients Infected With SARS-CoV-2 in Wuhan, China. 2020 Feb 19. doi: 10.1111/all.14238
84. Guan WJ, Ni ZY, Hu Y, et al., for the China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. doi: 10.1056/NEJMoa2002032
85. Xiaochen Li, Shuyun Xu, Muqing Yu, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. Journal of Allergy and Clinical Immunology. 2020 Apr 9. doi: 10.1016/j.jaci.2020.04.006
86. Yang Jing, Ya Zheng, Xi Gou, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12. doi: 10.1016/j.ijid.2020.03.017
87. Vardava CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence Tob Induc Dis. 2020;18:20. doi: 10.18332/tid/119324
88. Global initiative for asthma (GINA) 2020. https://ginasthma.org/
gina-reports/
89. Global initiative on chronic obstructive pulmonary disease (GOLD) 2020. https://goldcopd.org/gold-covid-19-guidance/
90. Naicker S, Yang CW, Hwang SJ, et al. The Novel Coronavirus 2019 Epidemic and Kidneys. Kidney Int. 2020. doi: 10.1016/j.kint.2020.03.001
91. Pan X-W, Xu D, Zhang H, et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020. 17.04.2020. doi: 10.1007/s00134-020-06026-1
92. Yao X, Li T, He Z, et al. Histopathological study on multiple sites of puncture of the remains of 3 cases of novel coronavirus pneumonia (COVID-19). Chin J Pathol. 2020;49. doi: 10.3760/cma.j.cn112151-20200312-00193
93. Huang C, Wang Y, Li X, et al. Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
94. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;201585. doi: 10.1001/jama.2020.1585
95. Yang X, Yu Y, Xu J, et al. Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
96. Deng Y, Liu W, Liu K, et al. Clinical Characteristics of Fatal and Recovered Cases of Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Retrospective Study. Chin Med J (Engl). 2020. doi: 10.1097/CM9.0000000000000824
97. Cheng Y, Luo R, Wang K, et al. Kidney Disease Is Associated With In-Hospital Death of Patients With COVID-19. Kidney Int. 2020;S0085-2538(20):30255-6. doi: 10.1016/j.kint.2020.03.005
98. Ma Y, Diao B, Lv X, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, China. Blog – NephJC. 2020. doi: 10.1101/2020.02.24.20027201
99. Information on COVID-19 coronavirus infection. Association of Nephrologists. 17.04.2020 (In Russ.) http://www.rusnephrology.org/professional/
100. Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney Int. 2020. doi: 10.1016/j.kint.2020.03.015
101. Available from: https://www.era-edta.org/en/covid-19-newsand-information/#toggle-id-23
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России, Нижний Новгород, Россия;
3 ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е.А. Вагнера» Минздрава России, Пермь, Россия;
4 ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону, Россия;
5 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
6 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия;
7 АО «Казахский медицинский университет последипломного образования», Алма-Аты, Республика Казахстан;
8 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Москва, Россия;
9 ФГБОУ ВО «Кировский государственный медицинский университет» Минздрава России, Киров, Россия;
10 Белорусский государственный медицинский университет, Минск, Республика Беларусь;
11 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
12 ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова», Москва, Россия;
13 ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
14 ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России, Саратов, Россия;
15 УО «Гомельский государственный медицинский университет», Гомель, Республика Беларусь;
16 ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия;
17 Ереванский государственный медицинский университет, Ереван, Республика Армения;
18 ФГБОУ ВО «Кубанский государственный медицинский университет», Краснодар, Россия;
19 НАО «Казахский национальный медицинский университет им. С.Д. Асфендиярова», Алма-Аты, Республика Казахстан;
20 ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России, Челябинск, Россия
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Volga Research Medical University, Nizhny Novgorod, Russia;
3 Wagner Perm State Medical University, Perm, Russia;
4 Rostov State Medical University, Rostov-on-Don, Russia;
5 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
6 Endocrinology Research Centre, Moscow, Russia;
7 Kazakh Medical University of Continuing Education, Almaty, Republic of Kazakhstan;
8 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
9 Kirov State Medical University, Kirov, Russia;
10 Belarusian State Medical University, Minsk, Republic of Belarus;
11 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
12 Lomonosov Moscow State University, Moscow, Russia;
13 Voino-Yasenetski Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
14 Razumovsky Saratov State Medical University, Saratov, Russia;
15 Gomel State Medical University, Gomel, Republic of Belarus;
16 Kirov Military Medical Academy, Saint Petersburg, Russia;
17 Yerevan State Medical University, Yerevan, Republic of Armenia;
18 Kuban State Medical University, Krasnodar, Russia;
19 Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan;
20 South Ural State Medical University, Chelyabinsk, Russia